Chiltern Achieves Supplementary Accreditation From the Medicines and Healthcare Products Regulatory Agency
Chiltern International Limited (Chiltern), a global contract research organization (CRO), has announced that Chiltern Early Phase Limited, based in Ninewells Hospital and Medical School in Dundee, Scotland, has achieved Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).
Dr Brian Sanderson, Medical Director, Chiltern Early Phase, explains, “In November 2007, the MHRA launched a voluntary accreditation scheme for units conducting Phase 1 studies in the UK. The scheme is designed to provide assurance to sponsors and participants that the accredited units meet satisfactory standards of quality and safety with adherence to Good Clinical Practice as well as best medical practice for subject safety.”
There are two tiers of accreditation:
• Standard Accreditation – units accredited to this level will be accredited to carry out all Phase 1 trials except those First in Human (FIH) trials requiring Clinical Trial Expert Advisory Group of the Commission of Human Medicines (CTEAG) review.
• Supplementary Accreditation - units accredited to this level will be accredited to carry out all Phase 1 trials including those First in Human (FIH) trials requiring CTEAG review.
Glenn Kerkhof, Chiltern CEO, stated, “With the achievement of Supplementary Accreditation, Chiltern Early Phase is placed to offer a full range of early phase FIH/exploratory development studies including Proof of Concept/Translational Medicine studies. This accreditation augments our collaboration with the Tayside Academic Health Sciences Centre including the Clinical Research Centre for Proof of Concept studies.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
